Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 21, Issue 12, 2003, Pages 2237-2246

  Fukuoka, Masahiro ^a   Yano, Seiji ^b   Giaccone, Giuseppe ^b   Tamura, Tomohide ^b   Nakagawa, Kazuhiko ^b   Douillard, Jean Yves ^b   Nishiwaki, Yutaka ^b   Vansteenkiste, Johan ^b   Kudoh, Shinzoh ^b   Rischin, Danny ^b   Eek, Richard ^b   Horai, Takeshi ^b   Noda, Kazumasa ^b   Takata, Ichiro ^b   Smit, Egbert ^b   Averbuch, Steven ^b   Macleod, Angela ^b   Feyereislova, Andrea ^b   Dong, Rui Ping ^b   Baselga, José ^b  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT RESPONSE; ADULT; AGED; DRUG ANTAGONISM; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE; QUINAZOLINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0012381722     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.10.038     Document Type: Article

References (27)

1. Ferlay J, Bray F, Pisani P, et al: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0 (IARC, CancerBase No 5). Lyon France, IARC Press, 2001
2. Schiller J: Current standards of care in small-cell and non-small-cell lung cancer. Oncology 61:3-13, 2001 (suppl 1)
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
4. Ries L, Eisner M, Kosary C, et al: SEER Cancer Statistics Review, 1973-1998. Bethesda, MD, National Cancer Institute, 2001
5. Fossella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24:455-462, 1997
6. Klastersky J, Paesmans M: Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: Review of literature results. Lung Cancer 34:95-101, 2001 (suppl 4)
7. Shepherd F, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
8. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol I 15:2996-3018, 1997
9. Salomon D, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
10. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385, 1993
11. Fujino S, Enokibori T, Tezuka N, et al: A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer 32A:2070-2074, 1996
12. Pavelic K, Banjac Z, Pavelic J, et al: Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13:1133-1137, 1993
13. Volm M, Rittgen W, Drings P: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77:663-669, 1998
14. Lawrence D, Niu J: Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther 77:81-114, 1998
15. Negoro S, Nakagawa K, Fukuoka M, et al: Final results of a phase I intermittent dose-escalation trial of ZD1839 (Iressa) in Japanese patients with various solid tumours. Proc Am Soc Clin Oncol 20:324a, 2001 (abstr 1292)
16. Ranson M, Hammond L, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of phase I trial. J Clin Oncol 20:2240-2250, 2002
17. Kris M, Herbst R, Rischin D, et al: Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD1839 (Iressa), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 29:72, 2000 (suppl 1, abstr 231)
18. Green S, Weiss G: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
19. Cella D, Bonomi A, Lloyd S, et al: Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
20. Cella DF, Eton DT, Fairclough DL, et al: What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 55:285-295, 2002
21. Pocock S, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
22. Rowinsky EK: The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 60:1-14, 2000 (suppl 1)
23. Huisman C, Smit EF, Giaccone G, et al: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18:3722-3730, 2000
24. Fossella F, DeVore R, Kerr R, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
25. Shepherd FA, Fossella FV, Lynch T, et al: Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials. Semin Oncol 28:4-9, 2001
26. Rusch V, Klimstra D, Venkatraman E, et al: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522, 1997
27. Kris M, Natale RB, Herbst R, et al: A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 21:292, 2002 (abstr 1166)